Background: Because the natural history of atrial tachyarrhythmia (AT) is not known in patients with implantable cardioverter-defibrillators (ICDs) but without device-based atrial therapies, we aimed ...

The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

ICD recipients who do not meet guideline criteria have elevated risk for adverse outcomes. Medical decision making is under increased scrutiny, particularly when it involves the use of costly ...

"Appropriately selected patients with NICM have the potential to benefit from primary prevention ICD therapy…Besides consideration of ICD placement, attention to guideline-directed medical therapy and ...